Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 42,000 shares, a decline of 89.4% from the October 31st total of 396,100 shares. Based on an average trading volume of 263,800 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Raymond James cut their price objective on Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its position in shares of Xilio Therapeutics by 85.0% during the third quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock valued at $266,000 after buying an additional 155,337 shares during the last quarter. XTX Topco Ltd purchased a new position in Xilio Therapeutics during the second quarter worth about $32,000. Finally, Renaissance Technologies LLC increased its stake in Xilio Therapeutics by 18.3% in the 2nd quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock valued at $280,000 after buying an additional 45,554 shares during the last quarter. Institutional investors and hedge funds own 54.29% of the company’s stock.

Xilio Therapeutics Trading Up 0.8 %

XLO traded up $0.01 during midday trading on Wednesday, hitting $1.00. The company had a trading volume of 11,941 shares, compared to its average volume of 518,390. The stock’s 50 day moving average price is $0.92 and its 200 day moving average price is $0.94. Xilio Therapeutics has a 52 week low of $0.49 and a 52 week high of $1.93.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.